CD34 positive cells

A trial (unique identifier NCT00081913) explored whether the symptoms seen in intractable angina patients were improved with CD34+ cells. The direct cardiac injections of autologous CD34+cells showed an improvement in the Canadian Cardiovascular Society angina classification scale, frequency of angina and overall quality of life against controls. The absence of any adverse or new events such as heart failure was not reported suggesting the safety of the use of these cells in therapy.